Here’s Why Dynegy, Lattice Semiconductor, and Three Other Stocks Are in Spotlight Today

Page 1 of 2

Although the pivotal U.S. election is now just five days away, the markets are rather calm as all three major indexes are close to flat.

In this article, let’s take a closer look at Lattice Semiconductor (NASDAQ:LSCC), Depomed Inc (NASDAQ:DEPO), Finish Line Inc (NASDAQ:FINL), Viacom, Inc. (NASDAQ:VIAB), and Dynegy Inc. (NYSE:DYN) and see why these stocks are on investors’ radars today. In addition, we will discuss the hedge fund sentiment towards each company in question, based on data from the last round of 13F filings.

At Insider Monkey, we track around 750 hedge funds and institutional investors. Through extensive backtests, we have determined that imitating some of the stocks that these investors are collectively bullish on, can help retail investors generate double digits of alpha per year. The key is to focus on the small-cap picks of these funds, which are usually less followed by the broader market and allow for larger price inefficiencies (see the details here).

stock, market, marketing, street, wall, banking, investment, trader, trading, backgrounds, graph, data, growth, business, board, forecasting, ticker, global, number, abstract,

Lattice Semiconductor (NASDAQ:LSCC) shares have spiked by 19% after the company agreed to sell itself to Canyon Bridge Capital Partners for $8.30 per share in cash, the total value of the deal amounting to $1.3 billion including Lattice’s net debt. The purchase has been unanimously approved by the boards of both companies, and the deal is expected to be closed in early 2017. Among the funds in our database, five funds owned $17.6 million worth of Lattice Semiconductor (NASDAQ:LSCC)’s stock, which accounted for 2.80% of the float on June 30, versus 10 funds and $28.28 million, respectively, on March 31.

Follow Lattice Semiconductor Corp (NASDAQ:LSCC)

Depomed Inc (NASDAQ:DEPO) briefly surged on open due to a Bloomberg report that stated that both Daiichi and Mallinckrodt are said to be considering making bids for Depomed. Shares of Depomed have retraced to close to flat, however, as sentiment around the stock remains cautious. Depomed shares have rallied by 24% year-to-date so far in part due to anticipation that management might unlock value through various strategic alternatives. A total of 23 funds tracked by us owned shares of Depomed Inc (NASDAQ:DEPO) at the end of June, unchanged from that of the previous quarter.

Follow Assertio Therapeutics Inc (NASDAQ:ASRT)

Traders are watching Finish Line Inc (NASDAQ:FINL) after Susquehanna analyst Sam Poser upgraded the stock to ‘Positive’ from ‘Neutral’ and reiterated his $23 price target. Poser thinks management’s move to potentially sell JackRabbit is a positive as it will improve focus on Finish Line’s core operations. Despite the upgrade, shares of the stock are in the red today as some investors remain on the sidelines until a more positive catalyst appears. The number of funds from our database with holdings in Finish Line Inc (NASDAQ:FINL) rose by five quarter-over-quarter to 21 at the end of June.

Follow Finish Line Inc (NASDAQ:FINL)

On the next page, we examine Viacom, and Dynegy.

Page 1 of 2